Oral-only partner therapy did not change recurrence in pooled analyses
Bacterial vaginosis keeps returning for too many patients after standard antimicrobial treatment, and this systematic review asks a question clinicians have circled for years: does treating the male partner help break the cycle? The answer depends on what is actually prescribed. Across 11 included studies, six randomized controlled trials contributed to the meta-analysis, and oral-only male partner treatment did not produce a significant reduction in recurrence at 4–5 weeks or at 12–16 weeks. At the earlier time point, the pooled estimate sat close to null, with an OR of 0.90 and a 95% CI of 0.57–1.40. At 12–16 weeks, the oral-only signal remained absent, with a pooled OR of 1.17 and a 95% CI of 0.78–1.77.
The biology behind that finding is plausible. Bacterial vaginosis is not simply a female-host condition with isolated vaginal dysbiosis; recurrence can reflect persistent microbial exchange and reintroduction from genital reservoirs. Oral therapy alone may fail to clear organisms harbored on the penile skin or in the urethral compartment, leaving a route for recolonization after the patient finishes treatment. In that setting, an oral-only regimen can look active on paper while still missing the anatomical sites most likely to sustain reinfection.
One sentence captures the clinical disappointment: oral-only treatment did not shift recurrence in either pooled time window.
The review also makes a careful methodological distinction that matters at the bedside. Trials assessing oral-only and combined oral-topical regimens at 12–16 weeks were not pooled together, because they were clinically and pharmacologically distinct. That approach avoids flattening different biological strategies into a single average effect and prevents a combined estimate from obscuring a regimen that reaches the genital reservoirs more effectively. The result is a more useful interpretation for clinicians, who need to know not just whether partner treatment works, but which version of partner treatment has a realistic chance of preventing relapse.
Five additional studies were handled narratively rather than meta-analytically, and the qualitative findings pointed toward good partner acceptability. That matters in a condition where adherence, relationship dynamics, and willingness to treat both members of a couple can determine whether a regimen is even attempted. Acceptability does not prove efficacy, but it does remove one common barrier to implementation. If couples are willing to use a partner-based strategy, the remaining question becomes whether the regimen matches the underlying microbiology.
Combined oral and topical treatment produced the strongest signal
The most striking result came from the single trial evaluating a combined oral and topical regimen. In that study, recurrence was significantly reduced, with an OR of 0.31 and a 95% CI of 0.15–0.62. The magnitude of the effect is hard to ignore, especially when contrasted with the flat oral-only results. Combined treatment likely works because it addresses more than one reservoir at once: systemic exposure may suppress urethral colonization, while topical therapy can target penile-skin bacteria that oral medication may not fully clear. That dual approach is biologically coherent in a recurrence-prone infection that appears to involve repeated exchange between partners rather than a one-way relapse in the vaginal environment alone.
The clinical implications are immediate, but they are not interchangeable across regimens. This systematic review does not support routine oral-only male partner treatment for recurrent bacterial vaginosis. The evidence instead separates partner therapy into two categories: a weak or absent signal for oral-only regimens, and a much more compelling signal for combined oral-topical therapy. Several guideline bodies have recently endorsed combined-regimen partner treatment, and this review aligns with that direction without overstating what the literature can prove. It also explains why “male partner treatment” should not be treated as a single intervention in future trials, guidelines, or practice discussions.
A practical takeaway emerges from the structure of the evidence itself. Recurrence prevention likely depends on whether treatment reaches both urethral and penile-skin reservoirs, not merely on whether the male partner swallows an antibiotic. For patients who have already gone through repeated cycles of infection and retreatment, that distinction can determine whether the next episode arrives in weeks or is avoided altogether. Even so, the evidence base remains uneven: the strongest positive result rests on one trial, while the broader oral-only literature remains unrevealing. That makes regimen-specific interpretation essential.
The review was registered in PROSPERO under CRD420251111546, and no specific grant supported the work. Ethical approval was not required because the analysis synthesized published studies. The authors declared no competing interests. Those details do not change the effect estimates, but they do reinforce that the findings come from a systematic attempt to organize an otherwise fragmented literature around a very specific clinical question.
For now, the message is narrow. Treating the male partner with oral medication alone has not shown a reliable benefit in preventing recurrent bacterial vaginosis. Combined oral and topical therapy appears more biologically sound and more effective, but the evidence still needs expansion before every clinical setting can adopt it with confidence.